Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 371

1.

Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis.

Trauner M, Gindin Y, Jiang Z, Chung C, Subramanian GM, Myers RP, Gulamhusein A, Kowdley KV, Levy C, Goodman Z, Manns MP, Muir AJ, Bowlus CL.

JHEP Rep. 2019 Dec 5;2(1):100060. doi: 10.1016/j.jhepr.2019.11.004. eCollection 2020 Feb.

2.

Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.

Ratziu V, Sanyal A, Harrison SA, Wong VW, Francque S, Goodman Z, Aithal GP, Kowdley KV, Seyedkazemi S, Fischer L, Loomba R, Abdelmalek MF, Tacke F.

Hepatology. 2020 Jan 13. doi: 10.1002/hep.31108. [Epub ahead of print]

PMID:
31943293
3.

Identification of People Infected With Hepatitis C Virus Who Have Never Been Diagnosed.

Kowdley KV.

Gastroenterol Hepatol (N Y). 2019 Dec;15(12):669-671. No abstract available.

4.

Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.

Harms MH, de Veer RC, Lammers WJ, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, Trivedi PJ, Hirschfield GM, Pares A, Floreani A, Mayo MJ, Invernizzi P, Battezzati PM, Nevens F, Ponsioen CY, Mason AL, Kowdley KV, Hansen BE, Buuren HRV, van der Meer AJ.

Gut. 2019 Dec 16. pii: gutjnl-2019-319057. doi: 10.1136/gutjnl-2019-319057. [Epub ahead of print]

5.

A Pilot Genome-Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH.

Gawrieh S, Guo X, Tan J, Lauzon M, Taylor KD, Loomba R, Cummings OW, Pillai S, Bhatnagar P, Kowdley KV, Yates K, Wilson LA, Chen YI, Rotter JI, Chalasani N; NASH Clinical Research Network.

Hepatol Commun. 2019 Nov 3;3(12):1571-1584. doi: 10.1002/hep4.1439. eCollection 2019 Dec.

6.

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.

Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators.

Lancet. 2019 Dec 14;394(10215):2184-2196. doi: 10.1016/S0140-6736(19)33041-7. Epub 2019 Dec 5.

PMID:
31813633
7.

Current and potential treatments for primary biliary cholangitis.

Shah RA, Kowdley KV.

Lancet Gastroenterol Hepatol. 2020 Mar;5(3):306-315. doi: 10.1016/S2468-1253(19)30343-7. Epub 2019 Dec 2. Review.

PMID:
31806572
8.

Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort.

Khoudari G, Singh A, Noureddin M, Fritze D, Lopez R, Asaad I, Lawitz E, Poordad F, Kowdley KV, Alkhouri N.

World J Hepatol. 2019 Oct 27;11(10):710-718. doi: 10.4254/wjh.v11.i10.710.

9.

Correction: ACG Clinical Guideline: Hereditary Hemochromatosis.

Kowdley KV, Brown KE, Ahn J, Sundaram V.

Am J Gastroenterol. 2019 Dec;114(12):1927. doi: 10.14309/ajg.0000000000000469. No abstract available.

PMID:
31724994
10.

Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response.

Murillo Perez CF, Hirschfield GM, Corpechot C, Floreani A, Mayo MJ, van der Meer A, Ponsioen CY, Lammers WJ, Parés A, Invernizzi P, Carbone M, Maria Battezzati P, Nevens F, Kowdley KV, Thorburn D, Mason AL, Trivedi PJ, Lindor KD, Bruns T, Dalekos GN, Gatselis NK, Verhelst X, Janssen HLA, Hansen BE, Gulamhusein A; GLOBAL PBC Study Group.

Aliment Pharmacol Ther. 2019 Nov;50(10):1127-1136. doi: 10.1111/apt.15533. Epub 2019 Oct 17.

PMID:
31621931
11.

Current perspectives into the evaluation and management of hepatitis B: a review.

Manne V, Gochanour E, Kowdley KV.

Hepatobiliary Surg Nutr. 2019 Aug;8(4):361-369. doi: 10.21037/hbsn.2019.02.09. Review.

12.

Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis.

Gatselis NK, Goet JC, Zachou K, Lammers WJ, Janssen HLA, Hirschfield G, Corpechot C, Lindor KD, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A, Lygoura V, Nevens F, Mason AL, Kowdley KV, Ponsioen CY, Bruns T, Thorburn D, Verhelst X, Harms MH, van Buuren HR, Hansen BE, Dalekos GN; Global Primary Biliary Cholangitis Study Group.

Clin Gastroenterol Hepatol. 2020 Mar;18(3):684-692.e6. doi: 10.1016/j.cgh.2019.08.013. Epub 2019 Aug 13.

PMID:
31419573
13.

ACG Clinical Guideline: Hereditary Hemochromatosis.

Kowdley KV, Brown KE, Ahn J, Sundaram V.

Am J Gastroenterol. 2019 Aug;114(8):1202-1218. doi: 10.14309/ajg.0000000000000315. Erratum in: Am J Gastroenterol. 2019 Dec;114(12):1927.

PMID:
31335359
14.

Pediatric cholestatic liver disease: Successful transition of care.

Selvakumar PK, Hupertz V, Mittal N, Kowdley KV, Alkhouri N.

Cleve Clin J Med. 2019 Jul;86(7):454-464. doi: 10.3949/ccjm.86a.18140. Review.

15.

Epidemiologic features of a large hepatitis C cohort evaluated in a major health system in the western United States.

Mukhtar NA, Ness EM, Jhaveri M, Fix OK, Hart M, Dale C, Pratt C, Kowdley KV.

Ann Hepatol. 2019 Mar - Apr;18(2):360-365. doi: 10.1016/j.aohep.2018.12.003. Epub 2019 Apr 17.

16.

Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.

Harms MH, van Buuren HR, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, Hirschfield GM, Parés A, Floreani A, Mayo MJ, Invernizzi P, Battezzati PM, Nevens F, Ponsioen CY, Mason AL, Kowdley KV, Lammers WJ, Hansen BE, van der Meer AJ.

J Hepatol. 2019 Aug;71(2):357-365. doi: 10.1016/j.jhep.2019.04.001. Epub 2019 Apr 11.

PMID:
30980847
17.

Mechanisms and Treatments of Pruritus in Primary Biliary Cholangitis.

Shah RA, Kowdley KV.

Semin Liver Dis. 2019 May;39(2):209-220. doi: 10.1055/s-0039-1679918. Epub 2019 Mar 8. Review.

PMID:
30849783
18.

Obeticholic acid in primary biliary cholangitis: where we stand.

Manne V, Kowdley KV.

Curr Opin Gastroenterol. 2019 May;35(3):191-196. doi: 10.1097/MOG.0000000000000525.

PMID:
30844895
19.

Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis.

Handa P, Thomas S, Morgan-Stevenson V, Maliken BD, Gochanour E, Boukhar S, Yeh MM, Kowdley KV.

J Leukoc Biol. 2019 May;105(5):1015-1026. doi: 10.1002/JLB.3A0318-108R. Epub 2019 Mar 5.

PMID:
30835899
20.

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease.

Bernstein DE, Tran A, Martin P, Kowdley KV, Bourliere M, Sulkowski MS, Pockros PJ, Renjifo B, Wang D, Shuster DL, Cohen DE, Jacobson IM.

Kidney Int Rep. 2018 Oct 16;4(2):245-256. doi: 10.1016/j.ekir.2018.10.005. eCollection 2019 Feb.

21.

Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection.

Lawitz E, Poordad F, Anderson LJ, Vesay M, Kelly MM, Liu H, Gao W, Fernsler D, Asante-Appiah E, Robertson MN, Hanna GJ, Barr E, Butterton J, Kowdley KV, Hassanein T, Sahota A, Gordon SC, Yeh WW.

J Viral Hepat. 2019 Jun;26(6):675-684. doi: 10.1111/jvh.13079. Epub 2019 Mar 12.

PMID:
30739366
22.

Serum ferritin as a biomarker for NAFLD: ready for prime time?

Shah RA, Kowdley KV.

Hepatol Int. 2019 Mar;13(2):110-112. doi: 10.1007/s12072-019-09934-7. Epub 2019 Feb 9. No abstract available.

PMID:
30739262
23.

The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.

Trauner M, Gulamhusein A, Hameed B, Caldwell S, Shiffman ML, Landis C, Eksteen B, Agarwal K, Muir A, Rushbrook S, Lu X, Xu J, Chuang JC, Billin AN, Li G, Chung C, Subramanian GM, Myers RP, Bowlus CL, Kowdley KV.

Hepatology. 2019 Sep;70(3):788-801. doi: 10.1002/hep.30509. Epub 2019 Mar 10.

24.

Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis.

Cheung AC, Lammers WJ, Murillo Perez CF, van Buuren HR, Gulamhusein A, Trivedi PJ, Lazaridis KN, Ponsioen CY, Floreani A, Hirschfield GM, Corpechot C, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, Nevens F, Thorburn D, Mason AL, Carbone M, Kowdley KV, Bruns T, Dalekos GN, Gatselis NK, Verhelst X, Lindor KD, Lleo A, Poupon R, Janssen HLA, Hansen BE; Global PBC Study Group.

Clin Gastroenterol Hepatol. 2019 Sep;17(10):2076-2084.e2. doi: 10.1016/j.cgh.2018.12.028. Epub 2019 Jan 4.

PMID:
30616022
25.

Financial Compensation For Hepatologists in Different Practice Settings.

Shiffman ML, Sussman NL, Ravendhran N, Ditmyer M, Kowdley KV, Kugelmas M.

Hepatology. 2019 Jun;69(6):2664-2671. doi: 10.1002/hep.30488. Epub 2019 Mar 12.

PMID:
30586171
26.

Haptoglobin 2 Allele is Associated With Histologic Response to Vitamin E in Subjects With Nonalcoholic Steatohepatitis.

Banini BA, Cazanave SC, Yates KP, Asgharpour A, Vincent R, Mirshahi F, Le P, Contos MJ, Tonascia J, Chalasani NP, Kowdley KV, McCullough AJ, Behling CA, Schwimmer JB, Lavine JE, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN).

J Clin Gastroenterol. 2019 Nov/Dec;53(10):750-758. doi: 10.1097/MCG.0000000000001142.

PMID:
30586008
27.

Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation.

Cardona-Gonzalez MG, Goldman JD, Narayan L, Brainard DM, Kowdley KV.

Hepatol Commun. 2018 Nov 14;2(12):1446-1450. doi: 10.1002/hep4.1280. eCollection 2018 Dec.

28.

You are what you wheat: effects of a whole-wheat diet compared with a refined-wheat diet on hepatic steatosis.

Manne V, Kowdley KV.

Am J Clin Nutr. 2018 Dec 1;108(6):1162-1163. doi: 10.1093/ajcn/nqy300. No abstract available.

PMID:
30541092
29.

Diagnosis and Management of Primary Biliary Cholangitis.

Younossi ZM, Bernstein D, Shiffman ML, Kwo P, Kim WR, Kowdley KV, Jacobson IM.

Am J Gastroenterol. 2019 Jan;114(1):48-63. doi: 10.1038/s41395-018-0390-3. Review.

PMID:
30429590
30.

Hepatic R2* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease.

Bashir MR, Wolfson T, Gamst AC, Fowler KJ, Ohliger M, Shah SN, Alazraki A, Trout AT, Behling C, Allende DS, Loomba R, Sanyal A, Schwimmer J, Lavine JE, Shen W, Tonascia J, Van Natta ML, Mamidipalli A, Hooker J, Kowdley KV, Middleton MS, Sirlin CB; NASH Clinical Research Network (NASH CRN).

J Magn Reson Imaging. 2019 May;49(5):1456-1466. doi: 10.1002/jmri.26312. Epub 2018 Oct 14.

PMID:
30318834
31.

Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.

Jayakumar S, Middleton MS, Lawitz EJ, Mantry PS, Caldwell SH, Arnold H, Mae Diehl A, Ghalib R, Elkhashab M, Abdelmalek MF, Kowdley KV, Stephen Djedjos C, Xu R, Han L, Mani Subramanian G, Myers RP, Goodman ZD, Afdhal NH, Charlton MR, Sirlin CB, Loomba R.

J Hepatol. 2019 Jan;70(1):133-141. doi: 10.1016/j.jhep.2018.09.024. Epub 2018 Oct 4.

32.

Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis.

Chalasani N, Abdelmalek MF, Loomba R, Kowdley KV, McCullough AJ, Dasarathy S, Neuschwander-Tetri BA, Terrault N, Ferguson B, Shringarpure R, Shapiro D, Sanyal AJ.

Liver Int. 2019 May;39(5):924-932. doi: 10.1111/liv.13974. Epub 2019 Feb 21.

PMID:
30253043
33.

Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.

Loomba R, Sanyal AJ, Kowdley KV, Terrault N, Chalasani NP, Abdelmalek MF, McCullough AJ, Shringarpure R, Ferguson B, Lee L, Chen J, Liberman A, Shapiro D, Neuschwander-Tetri BA.

Gastroenterology. 2019 Jan;156(1):88-95.e5. doi: 10.1053/j.gastro.2018.09.021. Epub 2018 Sep 15.

34.

No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.

Sarrazin C, Cooper CL, Manns MP, Reddy KR, Kowdley KV, Roberts SK, Dvory-Sobol H, Svarovskia E, Martin R, Camus G, Doehle BP, Stamm LM, Hyland RH, Brainard DM, Mo H, Gordon SC, Bourliere M, Zeuzem S, Flamm SL.

J Hepatol. 2018 Dec;69(6):1221-1230. doi: 10.1016/j.jhep.2018.07.023. Epub 2018 Aug 9.

PMID:
30098373
35.

Editorial: frequency of surveillance and survival in hepatocellular carcinoma.

Senussi NH, Kowdley KV.

Aliment Pharmacol Ther. 2018 Jul;48(2):228-229. doi: 10.1111/apt.14805. No abstract available.

36.

Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.

Siddiqui MS, Vuppalanchi R, Van Natta ML, Hallinan E, Kowdley KV, Abdelmalek M, Neuschwander-Tetri BA, Loomba R, Dasarathy S, Brandman D, Doo E, Tonascia JA, Kleiner DE, Chalasani N, Sanyal AJ; NASH Clinical Research Network.

Clin Gastroenterol Hepatol. 2019 Jan;17(1):156-163.e2. doi: 10.1016/j.cgh.2018.04.043. Epub 2018 Apr 26.

37.

Chronic Hepatitis C in Elderly Patients: Current Evidence with Direct-Acting Antivirals.

Jhaveri MA, Manne V, Kowdley KV.

Drugs Aging. 2018 Feb;35(2):117-122. doi: 10.1007/s40266-017-0515-1. Review.

PMID:
29417462
38.

Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA.

Chhatwal J, Chen Q, Ayer T, Bethea ED, Kanwal F, Kowdley KV, Wang X, Roberts MS, Gordon SC.

Aliment Pharmacol Ther. 2018 Apr;47(7):1023-1031. doi: 10.1111/apt.14527. Epub 2018 Jan 29.

39.

Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis.

Rao BB, Lashner B, Kowdley KV.

Inflamm Bowel Dis. 2018 Jan 18;24(2):269-276. doi: 10.1093/ibd/izx056. Review. Erratum in: Inflamm Bowel Dis. 2018 Nov 29;24(12):2656.

PMID:
29361103
40.

Research priorities for the discovery of a cure for chronic hepatitis B: Report of a workshop.

Block TM, Alter H, Brown N, Brownstein A, Brosgart C, Chang KM, Chen PJ, Cohen C, El-Serag H, Feld J, Gish R, Glenn J, Greten TF, Guo JT, Hoshida Y, Kowdley KV, Li W, Lok AS, McMahon B, Mehta A, Perrillo R, Rice CM, Rinaudo J, Schinazi RF, Shetty K.

Antiviral Res. 2018 Feb;150:93-100. doi: 10.1016/j.antiviral.2017.12.006. Epub 2017 Dec 14.

41.

Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.

Harms MH, Lammers WJ, Thorburn D, Corpechot C, Invernizzi P, Janssen HLA, Battezzati PM, Nevens F, Lindor KD, Floreani A, Ponsioen CY, Mayo MJ, Dalekos GN, Bruns T, Parés A, Mason AL, Verhelst X, Kowdley KV, Goet JC, Hirschfield GM, Hansen BE, van Buuren HR; Global PBC Study Group.

Am J Gastroenterol. 2018 Feb;113(2):254-264. doi: 10.1038/ajg.2017.440. Epub 2017 Dec 12.

PMID:
29231188
42.

Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.

Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Goodman ZD, Chalasani NP, Kowdley KV, George J, Lindor K.

Hepatology. 2018 Jul;68(1):349-360. doi: 10.1002/hep.29721.

43.

Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Chalasani NP, Anstee QM, Kowdley KV, George J, Goodman ZD, Lindor K.

Hepatology. 2018 Jul;68(1):361-371. doi: 10.1002/hep.29724.

44.

Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history.

Murillo Perez CF, Goet JC, Lammers WJ, Gulamhusein A, van Buuren HR, Ponsioen CY, Carbone M, Mason A, Corpechot C, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Thorburn D, Hirschfield G, LaRusso NF, Lindor KD, Zachou K, Poupon R, Trivedi PJ, Verhelst X, Janssen HLA, Hansen BE; GLOBAL PBC Study Group.

Hepatology. 2018 May;67(5):1920-1930. doi: 10.1002/hep.29717. Epub 2018 Apr 6.

45.

Third-trimester tenofovir to prevent mother-to-child hepatitis B virus transmission.

Burman BE, Jhaveri MA, Kowdley KV.

Indian J Med Res. 2017 Jul;146(1):1-4. doi: 10.4103/ijmr.IJMR_315_17. No abstract available.

46.

Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.

Manne V, Handa P, Kowdley KV.

Clin Liver Dis. 2018 Feb;22(1):23-37. doi: 10.1016/j.cld.2017.08.007. Epub 2017 Oct 18. Review.

PMID:
29128059
47.

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis.

Kowdley KV, Luketic V, Chapman R, Hirschfield GM, Poupon R, Schramm C, Vincent C, Rust C, Parés A, Mason A, Marschall HU, Shapiro D, Adorini L, Sciacca C, Beecher-Jones T, Böhm O, Pencek R, Jones D; Obeticholic Acid PBC Monotherapy Study Group.

Hepatology. 2018 May;67(5):1890-1902. doi: 10.1002/hep.29569. Epub 2018 Jan 29.

48.

An Update on the Treatment and Follow-up of Patients with Primary Biliary Cholangitis.

Burman BE, Jhaveri MA, Kowdley KV.

Clin Liver Dis. 2017 Nov;21(4):709-723. doi: 10.1016/j.cld.2017.06.005. Epub 2017 Jul 26. Review.

PMID:
28987258
49.

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.

Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry PS, Hezode C, Marinho RT, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng TI, Krishnan P, Lin CW, Mensa FJ.

Clin Gastroenterol Hepatol. 2018 Mar;16(3):417-426. doi: 10.1016/j.cgh.2017.09.027. Epub 2017 Sep 22.

PMID:
28951228
50.

A research agenda for curing chronic hepatitis B virus infection.

Alter H, Block T, Brown N, Brownstein A, Brosgart C, Chang KM, Chen PJ, Chisari FV, Cohen C, El-Serag H, Feld J, Gish R, Glenn J, Greten T, Guo H, Guo JT, Hoshida Y, Hu J, Kowdley KV, Li W, Liang J, Locarnini S, Lok AS, Mason W, McMahon B, Mehta A, Perrillo R, Revill P, Rice CM, Rinaudo J, Schinazi R, Seeger C, Shetty K, Tavis J, Zoulim F.

Hepatology. 2018 Mar;67(3):1127-1131. doi: 10.1002/hep.29509. Epub 2018 Jan 24. No abstract available.

Supplemental Content

Loading ...
Support Center